Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.
FDA Advisory Committee Recommends Approval of Shield Blood Test for CRC Detection in Average-Risk Adults
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC
FDA Approval Insights: Ponatinib in Ph+ ALL
Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease
FDA Approves Noninvasive Stool RNA Screening Test for CRC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies